INTRODUCTION
============

The functions of all eukaryotic cells depend on their ability to organize and distribute proteins, lipids, and nucleic acids to specific regions of the cell. This is largely achieved by dynamically sorting and sequestering specific molecules to membrane-bound subcellular organelles and the plasma membrane. The early sorting endosome and *trans*-Golgi network (TGN) play essential roles in these processes. One membrane trafficking pathway emerging from the sorting endosome leads retrograde in the secretory pathway to the TGN, connecting these key sorting stations for maintenance and regulation of cell structure and function. Some plasma membrane lipids are known to traffic retrograde all the way through the TGN into the endoplasmic reticulum (ER), an endogenous process co-opted by several bacterial toxins and viruses to cause disease. The retrograde pathways, however, have been difficult to measure with precision, sensitivity, and in real time. Biochemical assays for toxin transport into the Golgi and ER using protein sulfation and N-glycosylation to mark entry into TGN and ER, respectively, have proved highly informative, as has the use of ultrastructural electron and confocal light microscopy ([@B19]; [@B46]; [@B37]; [@B15]). But these approaches are time consuming, technically challenging, and difficult to quantify or apply with high temporal resolution or in high throughput for gene or small molecule discovery. Here, we describe the development and validation of a novel, highly sensitive, quantitative, and robust single-cell assay for measuring retrograde trafficking from PM to TGN and ER, effectively in real time.

RESULTS AND DISCUSSION
======================

Split-fluorescent protein toxin reporter
----------------------------------------

To model retrograde endosome sorting and transport, we applied the split fluorescent protein (split-FP) technologies ([@B12]) to *Vibrio cholerae* cholera toxin (CTx) and adapted the system to a flow cytometry assay. CTx typifies the family of AB~5~-subunit bacterial toxins that invade the ER of host cells to induce disease ([Figure 1, a and b](#F1){ref-type="fig"}) ([@B13]; [@B24]; [@B42]). For CTx, the homopentameric B-subunit binds the glycosphingolipid GM1 at the plasma membrane and GM1 carries the toxin retrograde by vesicular transport into the TGN and ER. Once in the ER, a portion of the A-subunit, the enzymatically active A1-chain ([Figure 1a](#F1){ref-type="fig"}, yellow), is dissociated from the B-subunit (red) and retro-translocated to the cytosol where it activates adenyl cyclase to cause disease. The other domain of the A-subunit, the A~2~-chain (cyan), remains assembled with the B-subunit in the ER lumen ([@B50]).

![Design, development, and validation of the split-fluorescence assay for retrograde trafficking. (a) Schematic of native holotoxin CTx structure and modifications to enable split-fluorescence complementation by fusing NG2 fragment mNG2~11~ to the N-terminus of the CTx A2-chain and reassembly with CTx B-subunit to form CTB-mNG2~11~. (b) Pathway of retrograde trafficking for CTB-mNG2~11~ from the plasma membrane into the Golgi and ER. (c) Retrograde trafficking to ER in K562 cells stably expressing ER-HA-mNG2~1-10~ as assessed by flow cytometry. Representative flow cytometry graph displayed to right. Cells were treated with CTB-mNG2~11~ for 4 h at 37°C; *n* = 3 independent experiments. (d) Time course of retrograde trafficking into the ER in K562 cells with 10 nM CTB-mNG2~11~---methods are as described above; *n* = 2 independent experiments. Representative flow cytometry graph shows timepoints at 0, 4, and 20 h for continuous CTB-mNG2~11~ toxin uptake and in cells treated with a 2-h toxin pulse and chase for 20 h. (e, f) Confocal microscopy of CTB-mNG2~11~ retrograde trafficking into TGN and ER of COS7 cells stably expressing TGN or ER mNG2~1-10~ and ER-mCherry, 6 h incubation. Cells were stained with anti-Golgin97 to mark the TGN. (g) TGN and ER retrograde trafficking in cells with 15 biological replications per condition (treated or not treated). Z-factors = 0.92 for TGN and 0.96 for ER retrograde transport. (h) Addition of tandem mNG2~11~ to CTx improves assay sensitivity. COS7 ER-HA-mNG2~1-10~ cells were treated with 10 nM holotoxin CT-1XmNG2~11~ or tandem CT-2XmNG2~11~ or CT-5XmNG2~11~ for 3.5 h at 37°C; *n* = 2 independent experiments. Error bars indicate ± SEM. \*\*\*\**p* \< 0.0001 (two-tailed Student's *t* test). Scale bars are 10 μm.](mbc-31-511-g001){#F1}

To develop a quantitative measure of retrograde trafficking, the N-terminus of the CTx A2-chain was fused to the split neon green2 (NG2) peptide mNG2~11~ ([Figure 1a](#F1){ref-type="fig"}, green). The fusion protein and CTx B-monomers were coexpressed in *Escherichia coli* and purified as an assembled mNG2~11~-A2-chain associated with the CTx-B~5~ pentamer ([Figure 1a](#F1){ref-type="fig"} and Supplemental Figure S1a). The modified toxin was called CTx B (CTB)-mNG2~11~. It contains all structural features that underlie the retrograde trafficking of CTX: binding to GM1 by the B-subunit and binding to the ER-retention KDEL-receptor by the C-terminal KDEL-motif of the A~2~-chain ([Figure 1b](#F1){ref-type="fig"}) ([@B24]; [@B42]). To measure trafficking of CTB-mNG2~11~ into the TGN or ER, we prepared several cell lines stably expressing the HA--epitope-tagged mNG2~1-10~ protein, including both adherent epithelial cells (human embryonic kidney \[HEK293T\] and African green monkey kidney COS7) and human lymphocyte K562 cells that grow in suspension. HA-mNG2~1-10~ was targeted to the TGN by fusing the molecule to the TGN targeting peptide from Gal-transferase (named TGN-HA-mNG2~1-10~) and to the ER by encoding the signal sequence from ER resident chaperone BIP and the C-terminal ER-retention motif KDEL (named ER-HA-mNG2~1-10~). In COS7 cells, TGN-HA-mNG2~1-10~ localized principally to the TGN as assessed by immunofluorescence and colocalization with the TGN resident protein Golgin97 (Supplemental Figure S1b) ([@B4]). TGN-HA-mNG2~1-10~ only marginally colocalized with the ER-mCherry marker when that was coexpressed (colocalization coefficients shown in Supplemental Figure S1c). Likewise, ER-HA-mNG2~1-10~ localized in COS7 cells only to the ER (Supplemental Figure S1, c and d). When exposed to CTB-mNG2~11~, all three cell lines expressing ER-HA-mNG2~1-10~ became fluorescent. We found slightly different toxin dose profiles across K562, HEK293T, and COS7 cells as assessed by flow cytometry ([Figure 1c](#F1){ref-type="fig"} and Supplemental Figure S1, e and f). Apparent ED50 was between 0.5 and 10 nM for retrograde trafficking, which corresponds closely to the ED50 for CTx-induced cell toxicity ([@B23], [@B22]). Time-course studies revealed temporal differences for the fluorescent signal induced by CTB-mNG2~11~. K562 cells had a more rapid rise to maximum fluoresce when compared with HEK293T and COS7 cells ([Figure 1d](#F1){ref-type="fig"} and Supplemental Figure S1, g and h). In pulse chase studies, both K562 and COS7 cells responded to CTB-mNG2~11~ with nearly the same signal ([Figure 1](#F1){ref-type="fig"}d and Supplemental Figure S1, g and h). Entry of CTB-mNG2~11~ into the Golgi or ER was verified by colocalization with Golgin97 or ER-mCherry in COS7 cells expressing TGN-HA-mNG2~1-10~ or ER-HA-mNG2~1-10~, respectively ([Figure 1, e and f](#F1){ref-type="fig"}). CTB-mNG2~11~ retrograde trafficking and colocalization was also observed in COS7 cells stably expressing Sec61β-HA-mNG2~1-10~, an ER-localized membrane-tethered mNG2~1-10~ by fusion with Sec61β (Supplemental Figure S1, c, i, and j). The variability in kinetics of retrograde trafficking observed among cell types highlights how endosomes can adapt to the physiologic needs of different cells and cell states---as well appreciated for signal transduction events ([@B20]).

To assess reproducibility and signal size, we studied 15 biologic replicates of K562 cells treated or not treated with CTB-mNG2~11~ using both the TGN and the ER transport assays. We found high levels of reproducibility with calculated Z-factors for discerning retrograde transport of 0.92 and 0.96, respectfully ([Figure 1g](#F1){ref-type="fig"}). Assays adapted for high-throughput screening are considered ideal if they have Z-factors \>0.5 ([@B52]). Signal sensitivity was enhanced by concatenating additional mNG2~11~ strands. The addition of multiple (concatenated) mNG2~11~ strands on CT-(EE/DD) progressively increased the PM to ER retrograde trafficking signal in COS7 cells ([Figure 1h](#F1){ref-type="fig"}). We found the split-FP technology system can also be applied to red fluorescence, as evidenced by adaptation of split sfmCherry2~11~ system ([@B12]) and generation of recombinant CTB-sfmCherry2~11~ (Supplemental Figure S1k). Thus, the toxin-based split-FP assay enables robust, quantitative, effectively real-time, and high-throughput measurements of retrograde trafficking into TGN or ER.

General utility
---------------

The utility of the assay was first assessed in HEK293T and K562 cells acutely treated with small molecules implicated in affecting endosome traffic ([Figure 2, a and b](#F2){ref-type="fig"}). Brefeldin A (BFA) causes collapse of the Golgi compartment into the ER and profoundly blocks the mechanics of vesicular transport into and out of the secretory pathway ([@B22]). In both HEK293T and K562 cells, BFA completely blocked CTB--mNG2~11~-induced fluorescence caused by trafficking into the ER ([Figure 2, a and b](#F2){ref-type="fig"}). BFA had no effect on expression of ER-HA-mNG2~1-10~ in either cell line (Supplemental Figure S2, a and b). Retrograde transport into the Golgi was also blocked by BFA ([Figure 2c](#F2){ref-type="fig"}), as observed before using other measures of retrograde transport ([@B13]). Also as expected ([@B19]), we found that treatment with nocodazole to depolymerize microtubules resulted in inhibition of retrograde ER trafficking in both cell lines.

![Quantitative measures of retrograde traffic under different conditions. (a, b) Retrograde trafficking to ER as assessed in K562 (a) and HEK293T (b) treated with the indicated compounds for 30 min before addition of CTB-mNG2~11~. Data normalized to Mock (untreated) cells; *n* = 3 independent experiments, each with three biologic replicates, and mean marked as one point for each condition. (c) Retrograde trafficking to TGN performed as in a; *n* = 3 independent experiments (BFA 10 µM). (d) Retrograde trafficking to ER in cells pretreated with DTT (4 mM) or tunicamycin (5 μg/ml); *n* = 3 independent experiments. (e) COS7 cells stably expressing ER-mCherry and ATLASTIN-K80A, CLIMP63, or DP1. (f) Retrograde trafficking to ER in cells overexpressing CLIMP63, DP1, or ATLASTIN1-K80A. Data normalized by CTB-Alexa Fluor 488 uptake; *n* = 5 independent experiments. (g) Retrograde trafficking to TGN as in f; *n* = 4 independent experiments. (h) Western blot for HA-epitope in HEK293T cells stably transfected with empty vector (EV), HA-tagged ATLASTIN-K80A, CLIMP63 or DP1, and HA-tagged TGN-mNG2~1-10~. Mean ± SEM, ns not significant, \**p* \< 0.05, \*\**p* \< 0.01, \*\*\**p* \< 0.001, \*\*\*\**p* \< 0.0001 (two-tailed Student's *t* test). Scale bars are 10 μm.](mbc-31-511-g002){#F2}

We then studied the poorly understood role and impact of intracellular calcium signaling on PM-ER retrograde trafficking using thapsigargin. Thapsigargin amplifies cytosolic Ca^2+^ levels by inhibition of the ER Ca^2+^-ATPase, thus also inducing ER stress. We found that thapsigargin inhibited retrograde transport from PM to ER ([Figure 2, a and b](#F2){ref-type="fig"}). While the ER stress-inducing (but nonspecific) reducing agent dithiothreitol (DTT) caused inhibition of retrograde ER trafficking, thus phenocopying the cells treated with thapsigargin, we observed no such effect in cells treated with tunicamycin, a small molecule that causes ER stress by blockade of N-glycosylation ([Figure 1d](#F1){ref-type="fig"}). Thus, thapsigargin likely inhibits retrograde membrane traffic via its effects on intracellular Ca^2+^ transients. Localized Ca^2+^ transients are well known to effect membrane traffic at nerve terminals, PM repair after injury, and exocytosis in secretory cell types ([@B2]; [@B8]; [@B1]). We also note that our result with thapsigargin differs from two previous studies, which used indirect measures of retrograde trafficking and different experimental systems ([@B36]; [@B41]; [@B53]), perhaps explaining the inconsistency.

In some cases, different cell lines exposed to the same treatments had different results. This was most readily evident in cells treated with cytochalasin D, which inhibits actin dynamics affecting endosome budding and movement ([@B21]; [@B33]) and in cells treated with Retro-2^cycl^, a small molecule recently found to block ER trafficking of the related AB~5~-subunit Shiga toxin ([Figure 2, a and b](#F2){ref-type="fig"}) ([@B43]; [@B10]). In both cases, HEK293T epithelial cells responded to drug treatments, but K562 cells did not. We also note the enhancing effect of blebbistatin, a myosin II inhibitor ([@B44]), on retrograde trafficking. This result suggests the possibility, among others, that actin--myosin-based motility affects structure and function of some organelles or sorting steps in the pathway.

In all cases of small molecule treatment, there were no detectable effects of drug treatments on expression of the split-FP ER-HA-mNG2~1-10~ as assessed by immunoblot (Supplemental Figure S2, a and b). Overall, our results highlight underappreciated, albeit in some cases expected, cell type-specific adaptations to endosome trafficking. They emphasize the value of the split FP-protein method for quantitative measurement of membrane transport with high degrees of temporal resolution.

Effects of ER structure: tubules and sheets
-------------------------------------------

Retrograde vesicular trafficking to the ER necessarily entails factors intrinsic to ER structure and function. To test whether such functionality can be detected by the split-FP trafficking assay, we studied cells altered in ER morphology by overexpression of a mutant form of the dynamin-like GTPase ATLASTIN1 K80A, the coiled-coiled ER-luminal spacer protein CLIMP63, or DP1 ([Figure 2e](#F2){ref-type="fig"}). Each of these ER intrinsic proteins affects the development and dynamics of ER tubules and sheets ([@B39])---amplifying ER tubules in cells overexpressing ATLASTIN1 K80A or DP1 and ER sheets in cells overexpressing CLIMP63 ([@B49]; [@B16]; [@B38]). When retrograde trafficking of CTB-mNG2~11~ was quantified in these cells, we found that overexpression of CLIMP63 and DP1 caused inhibition of transport into the ER compared with mock transfected cells ([Figure 2f](#F2){ref-type="fig"}). Remarkably, retrograde trafficking from PM into the TGN was also affected ([Figure 2g](#F2){ref-type="fig"}), implicating effects of ER structure on function of the closely related Golgi and TGN organelles. Overexpression of ATLASTIN1 K80A, in contrast, had reduced retrograde transport into the TGN but no detectable effect on trafficking into the ER. In all cases, expression levels of ER-HA-mNG2~1-10~ in the different transfected cells were the same, as assessed by immunoblot ([Figure 2h](#F2){ref-type="fig"}). The overall binding and uptake of Alexa-labeled CTxB was also assessed in each cell line under the same conditions---to control for this potentially confounding factor. There was no apparent effect on CTxB-Alexa uptake on overexpression of the various ER-altering proteins (Supplemental Figure S2c). Nevertheless, the results are shown normalized to the endocytic uptake of toxin among the different conditions. To test for the alternative possibility that the ER-shaping genes differentially affect membrane traffic by inducing an ER stress response, we used the same cell lines transfected with a luciferase reporter for IRE1α activation and XBP1 splicing ([@B51]; [@B17]). Here, we found that CLIMP63 induced a mild ER stress response relative to thapsigargin treatment, but ATLASTIN1 K80A and DP1 did not (Supplemental Figure S2d). This also did not correlate with the observed phenotypes.

Thus, it appears that ER morphology can affect retrograde membrane transport into the ER. The different effects obtained by overexpression of ATLASTIN1 K80A and DP1 suggest that ER shape, on its own, cannot fully explain the mechanism, as both conditions are predicted to amplify ER tubules relative to sheets. And in the case of the ATLASTIN K80A mutant, the disparity in results between PM to TGN and PM to ER trafficking suggests an alternative pathway from PM to ER that can bypass the TGN, as implicated before ([@B27]; [@B37]).

Application to human disease
----------------------------

Alterations in cell polarity and trafficking genes underlie the pathophysiology of a number of poorly understood monogenic disorders ([@B26]; [@B48]; [@B28]; [@B25]). In the intestine, polarized trafficking is critical for normal transport and barrier function. Congenital diarrheas and enteropathies are a group of disorders resulting from monogenic mutations in intestinal epithelial genes ([@B45]), including a subset of disorders involving alterations in cell polarity and/or loss of apical membrane structure and function. These include loss of function mutations in MYO5B resulting in microvillus inclusion disease ([@B11]; [@B30]) and in TTC7A ([@B7]; [@B34]) resulting in infantile-onset enterocolitis. MYO5B function has been described to be important in the apical recycling pathway, but how MYO5B affects other trafficking pathways is incompletely understood. Loss of TTC7A causes altered determination of apical-basal polarity; however, there is currently no information about how the loss of this gene function impacts cellular trafficking. As all endomembrane structures of eukaryotic cells are essentially a network of interconnected pathways, we reasoned that measuring retrograde CTB-mNG2~11~ trafficking in cells affected by these diseases may be informative of gene function and cellular phenotype. To test this, we used two unique shRNAs to knock down MYOVB or TTC7A in the human HEK293T cell line stably expressing TGN-HA-mNG2~1-10~ and ER-HA- mNG2~1-10~ (Supplemental Figure S3a). In both cases, and for both shRNAs against each gene, we found that trafficking from the PM into the TGN and ER was strikingly enhanced ([Figure 3, a--d](#F3){ref-type="fig"}). Again, these results were controlled for total CTxB-Alexa uptake (Supplemental Figure SS3b). These results could not have been predicted. They raise interesting hypotheses for how trafficking networks are interconnected and for the subcellular mechanisms that underlie these gene-specific pathophysiologies.

![Retrograde trafficking in monogenic human disease. (a) Knockdown of MYOVB and TTC7a using two unique shRNAs in HEK293T cells stably expressing TGN-HA-mNG2~1-10~ enhances retrograde trafficking to TGN. Data normalized to control shRNA at 20 nM CTB-mNG2~11~/CTB Alexa Fluor 488 loading; *n* = 4 independent experiments. (b, c) Representative flow cytometry graphs from a. (d) Retrograde trafficking to ER as in a. *n* = 3 independent experiments. (e) Retrograde trafficking to TGN in human iPSCs stably expressing TGN-HA-mNG2~1-10~ and treated or not with 2 μM GM1 C12:0. Error bars indicate ± SEM, ns not significant, \**p* \< 0.05, \*\**p* \< 0.01, \*\*\**p* \< 0.001 (two-tailed Student's *t* test).](mbc-31-511-g003){#F3}

Another significant impediment in our understanding of intracellular trafficking in human diseases has been the lack of a quantitative assay to easily and quantitatively monitor membrane sorting in primary cells. To address this problem, we prepared human-induced pluripotent stem cells (iPSCs) lines stably expressing TGN-HA-mNG2~1-10~. These undifferentiated cells, however, did not bind CTx in detectable amounts and gave no signal for retrograde transport ([Figure 3e](#F3){ref-type="fig"} and Supplemental Figure S3, c and d). When the iPSCs cell plasma membranes were loaded with exogenous purified GM1 glycosphingolipids (in this case, GM1 containing short C12:0 acyl chains in the ceramide domain, termed GM1-C12:0), the iPSCs transported CTB-mNG2~11~ into the TGN ([Figure 3e](#F3){ref-type="fig"}, GM1 lipid-treated cells)---thus validating a primary human iPSCs model for assessing membrane dynamics.

Concluding remarks
------------------

Space and time are the two elements of membrane sorting that fundamentally underlie cell order. In large part, however, the timing (and rates) of intracellular membrane movement have been underexamined due to the challenges of quantifying membrane trafficking events with precision, sensitivity, and ease. Here, we define a method that overcomes these barriers for the retrograde pathways followed by GM1 and CTx. Importantly, we note the split-FP technology can be easily expanded to employ other toxins, lectins, or endogenous receptor ligands amenable to molecular modifications and recombinant expression---such as the bacterial Shiga ([@B35]), exotoxin A ([@B5]), VacA ([@B29]; [@B55]), and anthrax toxins ([@B32]); the plant lectin ricin ([@B14]); and the extracellular signaling molecules epidermal growth factor or transferrin, which all follow different trafficking routes and engage other membrane processes underlying cellular function ([@B31]; [@B40]; [@B47]; [@B55]). In particular, the routes hijacked by VacA toxin from *Helicobacter pylori* (PM to mitochondria) ([@B9]) and exotoxin A from *Pseudomonas aeruginosa* (PM to nucleus) ([@B6]) are good examples of well-observed but poorly understood pathways that may be discerned using the split-FP technology.

Furthermore, systems level understanding of trafficking networks and dynamics require large data sets of quantitative measurements on membrane movement over space and time and across different cell types and cell states. Similar to systemwide approaches on modeling signaling transduction networks ([@B20]), the development of high throughput and quantitative trafficking technologies that assay for these factors will enable a fuller understanding of membrane traffic and sorting. We emphasize this approach can be applied in automation, in high throughput, and for gene or small molecule discovery, and the method has the power to compare endocytic networks across diverse immortalized cell lines or primary cells derived from normal or disease-affected individuals. These features, we argue, will enable systemwide analysis of membrane dynamics underlying cell function in health and disease with the potential for clinical translation.

MATERIALS AND METHODS
=====================

Plasmids
--------

CTB subunit was cloned into pET28a vector (Clontech). mNG2~11~ (and sfCherry2~11~ strands) were fused to CTx A2 strand and cloned into pGEXTEV-SUMO vector. Single 1× and tandem 2× and 5× mNG2~11~ were fused to the C-terminus of catalytically inactive (EE/DD) CTx A1 strand and cloned into pET24a (Clontech) with a His-SUMO tag. CTx A2 strand was cloned into pGEXTEV (a gift from Kim Orth, UT Southwestern). TGN-HA-mNG2~1-10~ was cloned by fusion of GALT sequence from GAL-transferase and a HA epitope to the N-terminus of mNG2~1-10~ into Ef1a-pHAGE-IRES-blasticidin vector derived from Ef1a-pHAGE-IRES-ZsGreen (obtained from the Harvard Plasmid Repository). The GFP was removed from the EF1a-pLVXGFP-N1 (Clontech) backbone and replaced with the human codon-­optimized TGN-FLAG-sfmCherry2~1-10~. CMV-pHAGE-IRES-Zsgreen ER- HA-mNG2~1-10~ was fused with ER targeting signal sequence from BIP at the N-­terminal and a C-terminal ER retention KDEL and cloned into Ef1a-pHAGE-IRES-blasticidin. ATLASITN1, CLIMP63, and DP1 cDNAs were obtained from the Harvard Plasmid Repository and cloned as HA-tagged fusion into CMV-pHAGE-IRES-ZsGreen (Harvard Plasmid Repository) or Ef1a-pHAGE-IRES-mCherry. ER-mCherry was cloned into pLVX-Puro (Clontech) using ER targeting signal sequence from BIP at the N-terminal and a C-terminal ER retention KDEL. Control short hairpin RNA (shRNA) targeting luciferase, MYOVB, and TTC7A were cloned into Ef1a-Puro-2a-mCherry-U6-shRNA vector. psPAX2 (Addgene plasmid 12260) was a gift from Didier Trono, EPFL. pCMV-VSVG was a gift from Bob Weinberg, MIT (Addgene 8454).

Protein purification
--------------------

Recombinant CTB-mNG2~11~ was expressed and purified by cotransformation of CTB pET28a and mNG2~11~-CTA2 pGEXTEV-SUMO into Shuffle T7 Express (NEB). Transformed cells were grown overnight in a 30°C incubator and restreaked onto a new plate and regrown overnight at 30°C. Next day, cells were inoculated into 2× YT and shook for 3--5 h at 35°C. Starter culture was used to inoculate into larger culture until OD~600~ = 1.0--1.2. Cells were induced at 18°C for 16--20 h with 0.4 mM isopropyl β-[d]{.smallcaps}-1-thiogalactopyranoside (IPTG). Cells were then collected and resuspended in 10 mM Tris, pH 8, 100 mM NaCl, 0.5% Triton X-100, and 1 mM phenylmethylsulfonyl fluoride and passed through an Emulsiflex C5 homogenizer (Avestin). The lysate was spun at 15,000 × *g* for 10 min, and supernatant was collected and used for purification by glutathione resin at 4°C. Eluted protein was cleaved with ULP1 protease and dialyzed overnight at 4°C in 10 mM Tris, pH 8, 100 mM NaCl. Next day, protein was dialyzed to 5 mM Na~2~PO~4~, pH 7, and purified by HiTrap SP HP column (GE Healthcare) using SP column Buffer A: 5 mM Na~2~PO~4~, pH 7, and gradient elution with Buffer B: 5 mM Na~2~PO~4~, pH 7, 1 M NaCl. Bound SP fractions containing CTB-mNG2~11~ were collected and run on SDS--PAGE gel and stained with Coomassie Blue reagent. Recombinant CTB-sfmCherry2~11~ was expressed as above but dialyzed in 10 mM Tris, pH 8.5, 150 mM NaCl overnight with ULP1 protease and then to 10 mM Tris, pH 8.5, 5 mM NaCl before purification by HiTrap Q HP column. Separation was performed using Buffer A: 20 mM Tris, pH 8.5, and Buffer B: 20 mM Tris, pH 8.5, 1 M NaCl. Recombinant purified CTA~2~-CTB complex was generated using CTA~2~ pGEXTEV and CTB in pET28a. Recombinant CTA~2~-CTB was cotransformed, expressed, and purified as above but with TEV protease to remove GST tag. Holotoxin CT-1×mNG2~11~, CT-2×mNG2~11~, and CT-5×mNG2~11~ were expressed and purified by expressing separately CTA~1~-1×mNG2~11,~ CTA~1~-2×mNG2~11~, or CTA~1~-5×mNG2~11~ subunits. CTA1 subunits were expressed and purified as above but with TEV protease to remove His~6~ tag cobalt resin. The CTA~1~ subunit was then incubated with purified CTA~2~-CTB complex overnight at 4°C in 10 mM Tris, pH 8, 150 mM NaCl to promote holotoxin assembly. Next day protein was dialyzed to S column A buffer. Holotoxin fractions were collected, and buffer was exchanged to Q column A buffer, 20 mM Tris, pH 8.5. Holotoxin fractions were collected using the HiTrap Q HP (GE Healthcare) separated by a salt gradient of Buffer B: 20 mM Tris, pH 8.5, 1 M NaCl. All recombinant protein were aliquoted and flash frozen by liquid nitrogen. For nucleotide sequence of split-FP toxin constructs, see Supplemental Table S1.

Cell culture
------------

K562 cells were grown in RPMI + 10% fetal bovine serum (FBS) pen/strep. HEK293T and COS7 cells were grown in DMEM + 10% FBS pen/strep. COS7 cells stably expressing ER-mCherry and TGN-HA-mNG2~1-10~ or ER-HA-mNG2~1-10~ were generated by lentiviral transduction by using packaging plasmids psPAX2 and pVSVG. K562 and HEK293Tcells were generated by lentivirus transduction and drug selection for TGN-HA-mNG2~1-10~, TGN-FLAG-sfmCherry2~1-10~, or ER-HA-mNG2~1-10.~ Human iPSCs growth and maintenance were followed as described previously in [@B54]. Human iPSCs were transduced and selected with blasticidin for transduced cells.TGN-HA-mNG2~1-10~ lentivirus was concentrated by low-speed centrifugation before transduction to iPSCs ([@B18]). Maintenance and incubation of cells were performed at 37°C + 5% CO~2~.

Western blotting
----------------

Cells were treated with respective treatments, harvested, and washed with 1× phosphate-buffered saline (PBS). Cells were lysed with 1× RIPA, 2 mM EDTA, and protease inhibitors. Lysates were spun at 20,000 × *g* for 5 min and supernatant collected. Sample buffer was added and heated for 10 min at 95°C. Samples were run on SDS--PAGE gels and immunoblotted with anti-HA for mNG2~1-10~, anti-actin as loading control. Proteins were detected using SuperSignal West Femto (Fisher Scientific). Images were taken with the Azure c300 system.

Confocal imaging
----------------

Confocal images were taken using a spinning disk confocal head coupled to an inverted Zeiss Axiovert 200 M microscope. To determine localization of stably expressing ER-mCherry and *trans*-Golgi and ER mNG2~1-10~, we utilized COS7 cells, which are commonly used for membrane trafficking and ER imaging studies. Cells were fixed with 4% paraformaldehyde and permeabilized with 0.2% saponin; anti-HA (Roche) was used to stain for mNG2~1-10~ and anti-Golgin97. To determine ER shape morphology of ER shape genes, COS7 cells stably expressing ER-mCherry were transfected with ALASTIN1-­K80A-IRES-ZsGreen, CLIMP63-IRES-ZsGreen, or DP1-IRES-ZsGreen. Cells were fixed and imaged as above. COS7 cells stably expressing ER-mCherry and Sec61β-HA-mNG2~1-10~, TGN-HA-mNG2~1-10~, or ER-HA-mNG2~1-10~ were treated with recombinant CTB-mNG2~11~ for 6 h. Cells were fixed, stained, and imaged as above. Pearson's and Mander's calculations were analyzed and calculated by Slidebook software (Intelligent 3i) using deconvolved images to generate masks by automatic threshold with the Otsu method.

Time-course retrograde assays
-----------------------------

K562 cells stably expressing ER-HA-mNG2~1-10~ were incubated with 10 nM CTB-mNG2~11~ at indicated times. Cells were spun down, washed with 1× PBS and resuspended in 1× PBS 2% FBS for flow cytometry. HEK293T and COS7 cells expressing Sec61β-HA-mNG2~1-10~ or ER-HA-mNG2~1-10~ were incubated with 20 nM CTB-mNG2~11~ at indicated times. Cells were collected and resuspended in 1× PBS 2% FBS for flow cytometry. Pulse-chase of CTB-mNG2~11~ was performed by incubation of CTB-mNG2~11~ for 2 h and incubated with cell culture media for 20 h before assayed by flow cytometry. Fluorescence positive gates were positioned relative to mock treated cells for all flow experiments.

Toxin dose retrograde assays
----------------------------

K562 cells stably expressing ER-HA-mNG2~1-10~ were treated with increasing concentrations of CTB-mNG2~11~ and incubated for 4 h at 37°C. Cells were collected and assayed by flow cytometry as above. COS7 and HEK293T cells stably expressing ER-HA-mNG2~1-10~ were treated with increasing concentrations of CTB-mNG2~11~ and incubated for 5 h at 37°C. Cells were collected and assayed by flow cytometry. K562 cells stably expressing TGN-FLAG-sfmCherry2~11~ were incubated 20 nM CTB-sfmCherry2~11~ for 5 h and assayed by flow cytometry.

Small molecular inhibitor retrograde assay
------------------------------------------

K562 cells stably expressing ER-HA-mNG2~1-10~ were pretreated with each compound for 30 min before incubation of 10 nM CTB-mNG2~11~ for an additional 4 h. HEK293T cells expressing ER-HA-mNG2~1-10~ were treated as above but incubated with 20 nM CTB-mNG2~11~ for 5 h. The final inhibitor concentrations used were DTT (4 mM), tunicamycin (5 μg/ml), BFA (5 μg/ml), Retro-2^cycl^ (25 μM), thapsigargin (300 nM), nocodazole (1 μM), cytochalasin D (10 μM), and blebbistatin (50 μM). [Figure 2, a--d](#F2){ref-type="fig"}, displays a positive percentage of fluorescence measurements pooled from independent experiments and normalized relative to CTB-mNG2~11~ with no inhibitor treatment.

ER-shape retrograde assays
--------------------------

Lentivirus packaged with EF1a-IRES-mCherry empty vector, HA-ATLASTIN-K80A, HA-CLIMP63, and HA-DP1 were transduced into HEK293T stably expressing ER-HA-mNG2~1-10~ cells. Retrograde assays were performed within 48--96 h after empty vector or ER shape gene transduction. Cells were incubated with 5 and 20 nM of CTB-mNG2~11~ for 5 h. Cells were washed with 1× PBS and harvested for flow cytometry. CTB-Alexa Fluor 488 (2 nM) was treated for each cell line to act as a toxin loading control. An individual experiment was normalized using the ratio of CTB-mNG2~11~/CTB-Alexa Fluor 488 to compare between cell lines and treatments. Data pooled from independent experiments were normalized relative to 20 nM CTB-mNG2~11~ empty vector treatment.

Monogenic genes retrograde assay
--------------------------------

Lentivirus packaged with shRNA against control targeting luciferase (Ctrl-sh) and two unique shRNAs each for MYOVB and TTC7A were produced. HEK293T cells stably expressing TGN-HA-mNG2~1-10~ were transduced with shRNA packaged lentivirus. Forty-eight hours after transduction, cells were selected for transduction and then plated for PM to Golgi retrograde assay the next day. Cells were incubated with 20 nM CTB-mNG2~11~ for 4 h, washed, and harvested to assay by flow cytometry. CTB-Alexa (2 nM) was used as loading control. Data were calculated as above but normalized relative to control shRNA treated with 20 nM CTB-mNG2~11~. For oligo nucleotide sequences of shRNAs, see Supplemental Table S2.

Primary cells retrograde assay
------------------------------

The control iPSC line, GON0515-03, is derived from a 30-yr-old male (IRB\# 10-02-0053) using Sendai virus reprogramming method, karyotypically normal at passage 5, and karyotyped after transducing with the Golgi split-mNG2 at passage 21. Human iPSCs were plated on Matrigel-coated plates with 10 μM rock inhibitor and iPSC-conditioned media. Cells were ± incubated with C12:0 GM1 lipid, which is known to traffic to the TGN. Lipid loading to cells was performed with 1:1 ratio of 2 μM lipid and 2 μM defatted bovine serum albumin resuspended in Advanced DMEM F12 for 10 min at 37°C. Cells were washed and then incubated with CTB-mNG2~11~ for 5 h at 37°C. Cells were collected with Accutase and resuspended in 1× PBS + 2% FBS and analyzed by flow cytometry.

Z-factor determination
----------------------

Fifteen biological replicates each for negative (Mock) and positive (CTB-mNG2~11~) conditions were used to calculate Z-factor scores for the *trans*-Golgi and ER retrograde assay. For the *trans*-Golgi Z-factor experiment, K562 cells stably expressing TGN-HA-mNG2~1-10~ were incubated with 10 nM CTB-mNG2~11~ for 5 h. Cells were spun and washed before assay by flow cytometry. PM to ER retrograde Z-factor experiment was performed as above but with ER-HA-mNG2~1-10~ at 4 h. Z-factor was calculated with the equation: Z = 1 -- [3 SD of sample]{.ul}± 3 SD of control│mean of sample -- mean of control│

XBP1 luciferase assay
---------------------

Firefly luciferase and renilla luciferase reagent was assayed with homemade luciferase reagent as stated previously ([@B3]). HEK293T cells were transfected with empty vector or corresponding ER-shape genes and XBP1-luciferase reporter and renilla luciferase with Fugene HD (Promega). Cells treated for 4 h with thapsigargin (300 nM) served as positive control.

qRT-PCR
-------

RNA was isolated by TRIzol (ThermoFisher) reverse transcribed with iScript cDNA Synthesis Kit (Bio-Rad) and qPCR by SYBR Green (Bio-Rad) on a CFX384 (Bio-Rad). Samples were normalized to actin. For qPCR primer sequences, see Supplemental Table S2.

Statistical analysis
--------------------

Significance was assessed using two-tailed *t* test \<0.05 was considered significant. Graphs were generated using GraphPad Prism.

Data availability
-----------------

Data that support the findings of this study are available from the corresponding author on request. Relevant DNA sequences are listed in the Supplemental Information.
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BFA

:   brefeldin A

CTx

:   cholera toxin

ER

:   endoplasmic reticulum

EV

:   empty vector

FBS

:   fetal bovine serum

HEK

:   human embryonic kidney

iPSC

:   induced pluripotent stem cell

NG2

:   split neon green2

PBS

:   phosphate-buffered saline

split-FP

:   split fluorescent protein

TGN

:   *trans*-Golgi network.
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